News summary
CITIC Construction Investment is concerned about the 2024 ASCO conference. Domestic innovative pharmaceutical companies have demonstrated innovation and clinical results in the field of oncology drugs. Many products have BIC potential, and subsequent progress is worthy of market expectations.
Newsletter text
CITIC Construction Investment pays attention to the progress of domestic innovative pharmaceutical companies at the 2024 ASCO Conference
At the 2024 ASCO conference, many domestic innovative pharmaceutical companies announcedcrashteamracingoriginalThe latest results of its clinical trials were reviewed. CITIC Construction Investment analysis pointed out that these pharmaceutical companies have performed particularly well in the field of cancer treatment, and the types of drugs involved include monoclonal antibodies, dual antibodies and ADCs, showing extremely high innovation and clinical effects. China's innovative pharmaceutical companies continue to invest in the field of cancer treatment. Many products have shown the potential to become the best drugs in their class, and future clinical trial results are highly anticipated.